168 related articles for article (PubMed ID: 35610242)
21. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Lambertini M; Agbor-Tarh D; Metzger-Filho O; Ponde NF; Poggio F; Hilbers FS; Korde LA; Chumsri S; Werner O; Del Mastro L; Caparica R; Moebus V; Moreno-Aspitia A; Piccart MJ; de Azambuja E
ESMO Open; 2020 Nov; 5(6):e000979. PubMed ID: 33154022
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
23. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
[No Abstract] [Full Text] [Related]
24. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.
Dębska-Szmich S; Kusińska R; Czernek U; Szydłowska-Pazera K; Habib-Lisik M; Piekarski JH; Olas E; Kulig A; Ułańska M; Kalinka-Warzocha E; Potemski P
Postepy Hig Med Dosw (Online); 2015 May; 69():586-97. PubMed ID: 25983297
[TBL] [Abstract][Full Text] [Related]
27. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
28. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
30. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
[TBL] [Abstract][Full Text] [Related]
31. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
Gavin PG; Song N; Kim SR; Lipchik C; Johnson NL; Bandos H; Finnigan M; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Geyer CE; Jeong JH; Costantino JP; Wolmark N; Paik S; Pogue-Geile KL
JAMA Oncol; 2017 Mar; 3(3):335-341. PubMed ID: 27812689
[TBL] [Abstract][Full Text] [Related]
32. Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy.
Gullo G; Bettio D; Zuradelli M; Masci G; Giordano L; Bareggi C; Tomirotti M; Salvini P; Runza L; La Verde N; Santoro A
Breast; 2013 Apr; 22(2):190-193. PubMed ID: 23473771
[TBL] [Abstract][Full Text] [Related]
33. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
35. Menopause is a determinant of breast adipose inflammation.
Iyengar NM; Morris PG; Zhou XK; Gucalp A; Giri D; Harbus MD; Falcone DJ; Krasne MD; Vahdat LT; Subbaramaiah K; Morrow M; Hudis CA; Dannenberg AJ
Cancer Prev Res (Phila); 2015 May; 8(5):349-58. PubMed ID: 25720743
[TBL] [Abstract][Full Text] [Related]
36. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
[TBL] [Abstract][Full Text] [Related]
37. p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.
Pavlakis K; Bobos M; Batistatou A; Kotoula V; Eleftheraki AG; Stofas A; Timotheadou E; Pentheroudakis G; Psyrri A; Koutras A; Pectasides D; Papakostas P; Razis E; Christodoulou C; Kalogeras KT; Fountzilas G
Pathol Oncol Res; 2015 Apr; 21(2):273-82. PubMed ID: 25098276
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer.
Honkanen TJ; Tikkanen A; Karihtala P; Mäkinen M; Väyrynen JP; Koivunen JP
Sci Rep; 2019 Jul; 9(1):10961. PubMed ID: 31358801
[TBL] [Abstract][Full Text] [Related]
39. Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis.
Chang MC; Eslami Z; Ennis M; Goodwin PJ
NPJ Breast Cancer; 2021 Jul; 7(1):97. PubMed ID: 34294716
[TBL] [Abstract][Full Text] [Related]
40. Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Le Du F; Carton M; Bachelot T; Saghatchian M; Pistilli B; Brain E; Loirat D; Vanlemmens L; Vermeulin T; Emile G; Gonçalves A; Ung M; Robert M; Jaffre A; Desmoulins I; Jouannaud C; Uwer L; Marc Ferrero J; Mouret-Reynier MA; Jacot W; Chevrot M; Delaloge S; Diéras V
Oncologist; 2023 Oct; 28(10):e867-e876. PubMed ID: 37589218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]